Table S3 from TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy
crossref（2023）
摘要
Median survival times in a CFPAC-1 peritoneal dissemination model after S-1, TAS-114, or S-1 and TAS-114 combination treatment
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要